UVEITIS CAUSED BY TREATMENT FOR MALIGNANT MELANOMA : A CASE SERIES
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Opthalmic Communications Society, Inc..
BACKGROUND/PURPOSE: To report the largest case series to date of uveitis occurring in association with immunomodulatory therapy for malignant melanoma.
METHODS: A retrospective multicenter case review. Twenty-two patients with uveitis occurring in association with either immunotherapy or targeted immune therapy for malignant melanoma were identified.
RESULTS: Of 22 patients, 11 had anterior uveitis in isolation. The remainder showed a variety of clinical features including panuveitis, ocular hypotony, papillitis, cystoid macular edema, and melanoma-associated retinopathy. Most patients responded well to treatment.
CONCLUSION: We report the largest case series to date of patients with uveitis secondary to drug treatment for malignant melanoma. These cases are likely to increase in number in the future as newer immunomodulatory therapies for cancers are developed and the indications for these drugs increase. A dilemma arises when patients respond well to these drugs but develop vision-threatening side effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Retinal cases & brief reports - 15(2021), 6 vom: 01. Nov., Seite 718-723 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Whist, Eline [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 03.12.2021 Date Revised 17.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/ICB.0000000000000876 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM298883163 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM298883163 | ||
| 003 | DE-627 | ||
| 005 | 20231225095133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/ICB.0000000000000876 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0996.xml |
| 035 | |a (DE-627)NLM298883163 | ||
| 035 | |a (NLM)31274846 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Whist, Eline |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a UVEITIS CAUSED BY TREATMENT FOR MALIGNANT MELANOMA |b A CASE SERIES |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.12.2021 | ||
| 500 | |a Date Revised 17.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Opthalmic Communications Society, Inc. | ||
| 520 | |a BACKGROUND/PURPOSE: To report the largest case series to date of uveitis occurring in association with immunomodulatory therapy for malignant melanoma | ||
| 520 | |a METHODS: A retrospective multicenter case review. Twenty-two patients with uveitis occurring in association with either immunotherapy or targeted immune therapy for malignant melanoma were identified | ||
| 520 | |a RESULTS: Of 22 patients, 11 had anterior uveitis in isolation. The remainder showed a variety of clinical features including panuveitis, ocular hypotony, papillitis, cystoid macular edema, and melanoma-associated retinopathy. Most patients responded well to treatment | ||
| 520 | |a CONCLUSION: We report the largest case series to date of patients with uveitis secondary to drug treatment for malignant melanoma. These cases are likely to increase in number in the future as newer immunomodulatory therapies for cancers are developed and the indications for these drugs increase. A dilemma arises when patients respond well to these drugs but develop vision-threatening side effects | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 700 | 1 | |a Symes, Richard J |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, John H |e verfasserin |4 aut | |
| 700 | 1 | |a Chowdhury, Vivek |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Li-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Grigg, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Ming-Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Karaconji, Tanya |e verfasserin |4 aut | |
| 700 | 1 | |a Giblin, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Symons, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Lyndell L |e verfasserin |4 aut | |
| 700 | 1 | |a McCluskey, Peter J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Retinal cases & brief reports |d 2007 |g 15(2021), 6 vom: 01. Nov., Seite 718-723 |w (DE-627)NLM187614776 |x 1937-1578 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2021 |g number:6 |g day:01 |g month:11 |g pages:718-723 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/ICB.0000000000000876 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2021 |e 6 |b 01 |c 11 |h 718-723 | ||